Advertisement

JNJ

Johnson & Johnson

Healthcare · USD

Set alert

Price alert · JNJ

All alert types
273.20 USD -2.00 -0.73%
As of Oct 30, 2026 Extended hours 273.48 +0.10%
Bid
273.13 × 100
Ask
273.23 × 200
273.15 Day range 282.00
186.00 52-week range 278.43
YTD
+32.01%
1 year
+44.51%
Open
280.00
Prev close
275.20
Mkt cap
657.68B
Vol
8.97M
Avg vol
6.85M
EPS
6.59
P/E
41.46
Div yield
1.95%
More statistics
Low
273.15
High
282.00
Forward P/E
23.51
Beta
0.21
Short ratio
2.23
Inst. own
76.77%
Dividend
5.36
Ex-div date
Nov 23, 2026
Earnings
Jan 20, 2027
50-d avg
265.48
200-d avg
246.71
1y target
279.41

5D chart

Chart tools
Interval
JNJ five-day price chart264.2268.7273.1277.6282.0Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
657.63B
Enterprise value
689.91B
Trailing P/E
41.45
Forward P/E
23.51
PEG ratio
3.10
Price / sales
6.62
Price / book
8.07
EPS (TTM)
6.59
Beta
0.21
Dividend yield
1.95%
Payout ratio
80.12%
Profit margin
16.20%
Revenue (TTM)
99.33B
Revenue growth
5.90%
Free cash flow
18.50B
Total cash
17.23B
Total debt
44.65B
Return on equity
20.02%
Shares outstanding
2.41B
Short % of float
0.78%
50-day average
265.48
200-day average
246.71

Analyst view

Consensus: buy

Buy
Price target (mean) 279.41 +2.3% upside
Target (low)
190.00
Target (mean)
279.41
Target (high)
320.00
Ratings (0m) 23 16 buy · 6 hold · 1 sell
  • Strong buy5
  • Buy11
  • Hold6
  • Sell1
  • Strong sell0

Next earnings

Jan 20, 2027

Expected Jan 20, 2027. Consensus EPS estimate 2.92.

Earnings history

Financials — quick view

All financials
JNJ Revenue — quarterly 25.40B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
JNJ Net income — quarterly 210.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
JNJ EPS — quarterly 0.09
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

JNJ recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 20, 2027Dec 27, 20262.91———
Oct 13, 2026Sep 27, 20262.522.59+0.07+2.78%
Jul 15, 2026Jun 28, 20262.852.90+0.05+1.75%
Apr 14, 2026Mar 29, 20262.682.70+0.02+0.75%
Jan 21, 2026Dec 28, 20252.462.460.000.00%
Oct 14, 2025Sep 28, 20252.762.80+0.04+1.45%

Upgrades / downgrades

JNJ analyst upgrades and downgrades
DateFirmActionFromTo
Oct 16, 2026Wells FargomainOverweightOverweight
Oct 15, 2026Morgan StanleymainOverweightOverweight
Oct 14, 2026Leerink PartnersmainOutperformOutperform
Oct 14, 2026Wells FargomainOverweightOverweight
Oct 14, 2026RBC CapitalmainOutperformOutperform
Oct 7, 2026GuggenheimreitBuyBuy

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
jnj.com

News

Your note

Sign in to keep a note on JNJ — it syncs with the Stock Master app.

Insider holders

JNJ insider holders
InsiderRelationLatest transactionDateShares held
BROADHURST VANESSAOfficerSaleJul 19, 202623,003
DECKER ROBERT JOfficerSaleFeb 26, 202624,462
DUATO JOAQUIN BOIXChief Executive OfficerSaleAug 12, 2026307,837
MULHOLLAND KRISTENOfficerConversion of Exercise of derivative securityFeb 12, 202619,830
REED JOHN COfficerConversion of Exercise of derivative securityApr 30, 202624,911
SCHMID TIMOTHYOfficerSaleSep 1, 202626,251

Institution ownership

JNJ institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.81%212,098,26457.94BJun 29, 2026
Vanguard Capital Management LLC6.53%157,226,37442.95BJun 29, 2026
State Street Corporation5.56%133,776,02536.54BJun 29, 2026
Vanguard Portfolio Management LLC2.67%64,370,81617.58BJun 29, 2026
Geode Capital Management, LLC2.45%59,086,41716.14BJun 29, 2026
JPMORGAN CHASE & CO2.42%58,301,60915.93BJun 29, 2026

Fund ownership

JNJ fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%76,421,62420.88BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%62,378,80217.04BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%32,111,3908.77BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%31,247,8488.54BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%29,810,7228.14BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Value Index Fund0.95%22,911,0236.26BJun 29, 2026
Advertisement